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Background
Advanced oxidation protein products (AOPPs) are carried
by oxidized plasma proteins, especially albumin, and are
important risk factors for cardiovascular events in patients
with renal disease. Renal patients have a high prevalence
of coronary and carotid arteriopathy and face an excessive
cardiovascular mortality. Therefore the role(s) of AOPPs
in the development of cardiovascular disease might be of
great importance.
Results
Herein, we demonstrate that albumin isolated from
hemodialysis (HD) patients and in vitro-generated AOPP-
albumin binds with high affinity to the high-density lipo-
protein (HDL) receptor scavenger receptor class B type-I
(SR-BI). AOPP-albumin blocked HDL association to SR-
BI and effectively inhibited SR-BI-mediated cholesterol
ester (CE) uptake, dependent on the AOPP content of
albumin. Furthermore, we demonstrate that AOPP-albu-
min effectively reduces SR-BI-mediated lipid tracer uptake
in mice. AOPP-albumin administration increased the
plasma half-life of [3H]CE-HDL in control mice 1.6-fold
(p = 0.01) and 8-fold (p = 0.0003) in mice infected with
adenoviral vectors encoding human SR-BI.
Conclusion
The observed inhibitory activity of albumin isolated from
HD patients is of clear physiological relevance. Our data
indicate that a physiological molar excess of HD-albumin
over HDL may block up to 50% of HDL-CE delivery to SR-
BI. Summing up, we provide strong in vivo and in vitro evi-
dence that AOPPs are proinflammatory mediators that
directly impair HDL metabolism and might therefore be
potential key players in the development of cardiovascu-
lar disease.
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